PriceTargets.com logo

Vyant Bio - VYNT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.19 As of 12/29/2023 10:03 PM ET
▲ +0.014 (7.78%)

This chart shows the closing price for VYNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vyant Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYNT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Vyant Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.19.

This chart shows the closing price for VYNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Vyant Bio. This rating has held steady since January 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/3/2023HC WainwrightDowngradeBuy ➝ Neutral
12/2/2022Ascendiant Capital MarketsLower Target$5.00
10/4/2022Ascendiant Capital MarketsInitiated CoverageBuy
5/17/2022HC WainwrightLower TargetBuy$15.00
3/8/2022HC WainwrightLower TargetBuy$25.00 ➝ $20.00
10/6/2021HC WainwrightInitiated CoverageBuy$25.00
(Data available from 12/17/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Vyant Bio logo
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.
Read More

Today's Range

Now: $0.19
Low: $0.18
High: $0.20

50 Day Range

MA: $0.19
Low: $0.19
High: $0.19

52 Week Range

Now: $0.19
Low: $0.14
High: $1.58

Volume

19,100 shs

Average Volume

161,822 shs

Market Capitalization

$1.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Vyant Bio?

The following sell-side analysts have issued stock ratings on Vyant Bio in the last year:
View the latest analyst ratings for VYNT.

What is the current price target for Vyant Bio?

0 Wall Street analysts have set twelve-month price targets for Vyant Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Vyant Bio in the next year.
View the latest price targets for VYNT.

What is the current consensus analyst rating for Vyant Bio?

Vyant Bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VYNT.

What other companies compete with Vyant Bio?

Other companies that are similar to Vyant Bio include Vsee Health, BioNexus Gene Lab, Union Dental, Agape ATP and Ethema Health. Learn More about companies similar to Vyant Bio.

How do I contact Vyant Bio's investor relations team?

Vyant Bio's physical mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The company's listed phone number is (201) 479-1357 and its investor relations email address is [email protected]. The official website for Vyant Bio is stemonix.com. Learn More about contacing Vyant Bio investor relations.